Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.
about
Prognosis and management of acute myeloid leukemia in patients with Down syndromeMyeloid leukemia in Down syndromeHomocysteine metabolism in children with Down syndrome: in vitro modulationTranscriptional regulation of the human cystathionine beta-synthase -1b basal promoter: synergistic transactivation by transcription factors NF-Y and Sp1/Sp3Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Improved outcome of acute myeloid leukaemia in Down's syndrome.Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathologyObatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Identification of novel cellular targets in biliary tract cancers using global gene expression technology.Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cellsImproved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report.An unexpected protein interaction promotes drug resistance in leukemia.
P2860
Q27016577-076438AB-4D37-4A01-851C-048577550342Q27027258-4263555A-A0B0-459E-9A9B-71E5E425589BQ28366367-B0A9506B-A770-4E4E-AC5F-735B9A195F3BQ28367210-81CA7E87-F699-4D17-B299-8B2E2C8D65A0Q28535006-3512D07A-766F-4AB9-8545-6A3F6A106CB7Q33662916-56796DEB-9F83-420D-9DB4-D72BF7696AF0Q33914289-6FD35073-EB64-408A-900D-9EF133B11A1AQ34081566-C3FA47E4-B9A6-4786-9B60-6C11D10DCCB2Q34352858-473D61FD-52FD-4E63-8123-BF0DDCC8BF14Q34544769-CC1273CE-4683-42BA-B379-ECD159CA7D73Q34611232-CF45414E-D9B3-4767-8F5A-EC4348D8B0EBQ35007971-6F425135-9CCD-4CAD-B694-EF0A2A31BC06Q35791572-998A533B-F72E-4AD8-8CCE-5CAD9F0DCC22Q36828315-47472BDD-CD4A-425E-8B0E-21397B5BE40EQ36843733-48307D31-CDA0-4BB8-9D61-01BF32CC6053Q37376388-E9BC459E-9E84-48D6-B4A4-EC72B4B04616Q37630747-382ACE6D-C51E-4769-A343-C01181C20554Q38733360-2B60CCA3-151D-4F21-926E-113E8973D0BCQ41009977-E5D4118F-BAD3-4AB2-A56F-51612DE1BD00Q42176458-4160660E-190B-4C49-BDE8-32BF29ED2E9AQ46158135-6C230829-3084-47BF-A5D4-C748A3BCBE20Q47094289-59886643-8242-439B-A9A7-ED7A99A21071
P2860
Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Enhanced metabolism of 1-beta- ...... n with acute myeloid leukemia.
@en
type
label
Enhanced metabolism of 1-beta- ...... n with acute myeloid leukemia.
@en
prefLabel
Enhanced metabolism of 1-beta- ...... n with acute myeloid leukemia.
@en
P2093
P1433
P1476
Enhanced metabolism of 1-beta- ...... n with acute myeloid leukemia.
@en
P2093
P304
P407
P577
1996-04-01T00:00:00Z